



Lymphoma Working Party

Chair: Bertram Glaß
Secretary: Anna Ossami Saïdy

Members & staff:

Norbert Schmitz (Member), Anna Sureda (Member), Peter Dreger (Member), Silvia Montoto (Member), Olivier Hermine (Member), Sascha Dietrich (Member), Chara Kyriakou (Member), Yasmina Serroukh, Ali Bazarbachi (Member), Alina Tanase (Member), Philipp Berning (member), Evgenii Shumilov (member), Imke Karsten (member), Maud Ngoya (Biostatistician), Mathilde Fekom (Biostatistician), Irma Khvedelidze (Study Coordinator), Hervé Finel (Study Coordinator)

Publications in 2023

Berning, P., Schmitz, N., Ngoya, M. *et al.* Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis. *Leukemia* 37, 1511–1520 (2023). <https://doi.org/10.1038/s41375-023-01924-x>

Mussetti A, Kanate AS, Wang T, et al. Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas. *Transplant Cell Ther.* 2023 Mar;29(3):184.e1-184.e9. doi: 10.1016/j.jct.2022.11.028. Epub 2022 Dec 25. PMID: 36577482; PMCID: PMC10316698. DOI: [10.1016/j.jct.2022.11.028](https://doi.org/10.1016/j.jct.2022.11.028)

Bruch, P-M., Dietrich, S., Finel, H. et al. Hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters. *Leukemia* 37(2): 465-472 (2023) doi: 10.1038/s41375-022-01782-z. Epub 2022 Dec 22. PMID: 36550212. DOI: [10.1038/s41375-022-01782-z](https://doi.org/10.1038/s41375-022-01782-z)

Penack, O., Peczynski, C., Sureda, A., et al. **Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma** *Front. Immunol.* 2023 Sep 27:14:1252811. doi: 10.3389/fimmu.2023.1252811. eCollection 2023.

Presentations at EBMT 2024

Oral Presentations

- **Liebers, N.**, (Germany) Outcomes of Brexucabtagene Autoleucl from ZUMA-2 and Allogeneic Stem Cell Transplantation in Relapsed/Refractory post-BTKI Mantle Cell Lymphoma.
- **Schmitz, N.**, (Germany) PTCL and AITL
- **Berning, P.**, NK/T-cell lymphoma
- **Hermine, O.**, (France) EATL

Manuscripts in Writing/Finalisation Phase

- **Shumilov, E.**, Trends in auto and allo SCT for T-cell Lymphoma
- **Berning, P., Sureda, A., Schmitz, N.**, Trends in DLBCL
- **Lopez, Pereira, P.**, Allo SCT for ATL HTLV-1
- **Perales, M-A.**, Allo HSCT For HL in the era of Checkpoint Inhibitors
- **Dietrich, S.**, ZUMA allo MCL

Active Studies

- **Berning, P., Kim, WS., Schmitz, N.**, Auto SCT in NK/TCL Lymphoma
- **Dreger, P., Kauer, J.**, HSCT for plasmablastic lymphoma
- **Karsten, I., Schmitz, N.**, Allo & auto SCT in hepatosplenic T-cell lymphoma
- **Martinez, C.**, Brentuximab consolidation for HL after high risk of relapse after auto HSCT
- **Renders, S., Dreger, P.**, T-cell histiocyte-rich Large B-cell Lymphoma (THRLBCL) >> comparison of outcome of **allo** in THRBCL vs DLBCL
- **Martinez, C.**, First Auto HSCT for HL refractory to BV responding to CPI
- **Renders, S., Dreger, P.**, T-cell histiocyte-rich Large B-cell Lymphoma (THRLBCL) >> comparison of outcome of **CAR-T vs allo** in THRBCL
- **Bazarbachi, A., Sureda, A.**, *Non-Interventional Study* - BV or CPI as bridge to auto SCT in HL

Upcoming Studies

- **Liebers, N., Dietrich, S.**, Allo SCT vs CAR T cell therapy in MCL – RWA
- **Kyriakou, C., Tournilhac, O.**, Waldentrom's Macroglobulinemia
- **Serroukh, Y., Montoto, S.**, SCT in indolent NHL